Project Grant R15CA293657
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$429K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award of $513,859, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to develop a novel adoptive cellular therapy platform using hematopoietic stem cells (HSCs) engineered with chimeric antigen receptor (CAR) technology. The goal is to generate a continuously renewing population of CAR-expressing natural killer (NK) cells that can provide long-term, safe, and efficacious anti-cancer immunity. The research aims to...
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Treatment Research" (CFDA 93.395), awarded a Project Grant of $402,600.00 to the Sloan-Kettering Institute for Cancer Research. The grant supports the development of novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 snRNP complex for the treatment of acute myeloid leukemia (AML). The key objectives are to (1) evaluate the efficacy and safety of U5 snRNP200-targeted CAR T cells,...
The National Cancer Institute (NCI) awarded a $193,797 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Washington University in St. Louis to investigate the mechanisms of natural killer (NK) cell activation and immune-editing of leukemia. The research aims to elucidate the transcription factors and epigenetic changes underlying conventional NK (CNK) versus memory-like NK (ML NK) cell anti-leukemia functionality, and to determine how ML NK cells edit the phenotype of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
This federal Project Grant award of $566,998.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research targeting acute myeloid leukemia (AML) using a CD123-directed NK-cell engager and NK cell immune therapy, as well as harnessing the apoptotic machinery through BCL-2 inhibition. The project will be performed by the University of Texas MD Anderson Cancer Center in Houston, TX over a period from September 30, 2024 to...
This Project Grant award of $458,698.00 was provided by the National Cancer Institute (NCI) under the federal Cancer Biology Research program (CFDA 93.396). The award, effective March 10, 2025 through February 28, 2030, supports research to identify novel genes and mechanisms underlying therapy resistance and relapse in acute myeloid leukemia (AML). The research aims to functionally validate candidate genes from prior single-cell RNA sequencing and CRISPR screens in order to better understand...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports scientific investigations focused on understanding the fundamental biological mechanisms underlying acute myeloid leukemia (AML). The $439,644 award to The Leland Stanford Junior University will be used to conduct functional studies of human AML stem cells, with the following key objectives: Investigate the relationship between specific genetic mutations and AML stem cell frequency, disease...
This federal Project Grant award from the National Cancer Institute (NCI), under CFDA Program 93.393 "Cancer Cause and Prevention Research", provides $678,204 to the University of Rochester to support a research project titled "A Decisional Intervention for Older Adults with Acute Myeloid Leukemia and Their Caregivers". The project aims to investigate therapeutic advances that have allowed more adults aged 60 years with acute myeloid leukemia (AML) to receive...
This $1,013,623 Project Grant awarded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to March Biosciences Inc. aims to develop dual-targeting chimeric antigen receptor (CAR) T-cell therapies for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma (TCL). The grant will fund the development of CD5/CD7.CAR-T cells derived from haploidentical, CD45RA-depleted donor T-cells (RAD-T) to target malignant T-cells with varying antigen expression....
The National Cancer Institute (NCI), under the Cancer Treatment Research (CFDA 93.395) federal grant program, awarded a $734,435 Project Grant to the Beckman Research Institute of the City of Hope on March 10, 2025. The grant supports research to overcome resistance to BH3 mimetic drugs, a targeted therapy for acute myeloid leukemia (AML), by inhibiting the ADSS2 enzyme involved in AMP biosynthesis. The research aims to: 1) Correlate ADSS2 levels with BH3 mimetic responsiveness in primary AML...